How do you choose the best, affordable treatment for each patient from 6 Million possible combinations for your patients with type 2?

Diabetes in Control is working with an endocrinologist and computer specialist who have developed a program to help you in deciding the best treatment option to manage blood glucose that the patient can afford using their insurance. They are looking for medical professionals to use it and provide feedback.

Would you be interested in learning about a free software that can go through 6 million possible drug combinations for patients with type 2, providing the best options for treatment using the patient’s medical information and insurance? It will rate each combination as to how much it could lower A1c, and provide the cost for each treatment, plus any side effects and even coupons, if available, for the patient to use. This program has already been used for hundreds of patients. See the software in action in a 9 minute video.

If you're interested in trying the software, email me at publisher@diabetesincontrol.com.

Follow the link to share your opinion or request more info.

A cross continuum of inpatient diabetes care. Hospitals are being incentivized for achieving diabetes care metrics in the patient population in their catchment area which has required them to develop effective healthcare delivery models that impact not only just individual patients but also the patient population as a whole. Hear case studies from Mayo Clinic, MD Anderson, UPMC, Allina Healthcare, Essentia Health and more. Learn about transitioning of care, building and maintaining Inpatient Diabetes Programs and Management, incorporating Triple Aim, diabetes prevention programs, ROI for Tele Diabetes, collaborative diabetes depression models, incorporating SOCIAL DETERMINANTS OF HEALTH measures, financial impact of low literacy on a healthcare system, Cardiovascular risk associated with diabetes and inpatient care, cancer risk associated with diabetes and the inpatient care, managing diabetes in hospitalized patients with chronic Kidney Disease and more. For complete conference details including discounts available for Diabetes In Control Members, click here.

New technologies have the potential to revolutionize diabetes care. But what are the advantages and disadvantages of insulin pumps, vs. daily injections? How widely will they be adopted, by patients with type 2 diabetes as well as type 1? What factors will make a difference for adoption – convenience, accuracy, costs? In November, we asked you to help us examine the future of insulin delivery and find the answers to these questions. Now we’re sharing all the results with you, so that you can see for yourself how your fellow members of the diabetes community plan on using CGMs, now and in the future.

Can you guess which article published this year was the most popular of all?

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. Here's a roundup of the interviews we published in 2018, so you can catch up on anything you may have missed.

In this week's Homerun Slides, another question from the Adrenal category in Dr. Claude Lardinois' Endocrinology Jeopardy! This week's clue: 44 year old female with hypertension and type 2 diabetes.

Maternally inherited diabetes and deafness (MIDD) most commonly results from heteroplasmic G to A substitution of the mitochondrial DNA at nucleotide pair 3243 in one of the two tRNA(Leu) genes. The same mutation that causes MIDD also causes a syndrome of severe neuromuscular disease called MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke). Within a family there is usually a dominant phenotype, although occasionally some members develop MIDD whilst others develop MELAS.

Diabetes in Control readers are being asked to participate in exclusive research that will provide new insights into what you think about insulin pumps and daily injections. Whether you’re a patient, a patient family member, medical professional or diabetes educator, we need to hear from you. Please take a few moments to take our survey and help our research. The survey takes only about 3 minutes, is completely anonymous, and lets you make your voice heard in analysis that can potentially influence the future of insulin delivery research and development.

Current and less-strict ADA recommendations found to achieve appropriate glycemic levels.

Dementia rates are higher among people who have type 1 diabetes and an A1C greater than 8%,